Human dosimetry of free ²¹¹At and meta-[²¹¹At]astatobenzylguanidine (²¹¹At-MABG) estimated using preclinical biodistribution from normal mice.

ABSTRACT:

Background

²¹¹At is one of the ideal nuclides for targeted radionuclide therapies (TRTs). Meta-[²¹¹At]astatobenzylguanidine (²¹¹At-MABG) has been proposed for the treatment of pheochromocytoma. To effectively use these radiopharmaceuticals, dosimetry must be performed. It is important to determine the absorbed doses of free ²¹¹At and ²¹¹At-MABG to determine the organs that may be at risk when using TRTs. The aim of this study was to estimate human dosimetry from preclinical biodistribution of free ²¹¹At and ²¹¹At-MABG in various organs in normal mice.

Methods

Male C57BL/6 N mice were administered 0.13 MBq of free ²¹¹At or 0.20 MBq of ²¹¹At-MABG by tail-vein injection. The mice

SUBMITTER: Ukon N 

PROVIDER: S-EPMC7509022 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature